What is the difference between Abaloparatide and Teriparatide?

Abaloparatide is classified as: Synthetic parathyroid hormone-related protein (PTHrP 1-34) analog; osteoanabolic agent. Teriparatide is classified as: Recombinant human parathyroid hormone fragment PTH(1-34); bone-forming (anabolic) osteoporosis agent. Abaloparatide is approved for one or more medical uses in at least one major jurisdiction. Teriparatide is approved for one or more medical uses in at least one major jurisdiction.

Is Abaloparatide or Teriparatide approved?

Abaloparatide is approved for one or more medical uses in at least one major jurisdiction. Teriparatide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Abaloparatide and Teriparatide?

Peptide Science Daily tracks 25 registered clinical trials for Abaloparatide (evidence grade A) and 182 for Teriparatide (evidence grade A).

Compound comparison

Abaloparatide vs Teriparatide

This page sets Abaloparatide and Teriparatide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Abaloparatide
Synthetic parathyroid hormone-related protein (PTHrP 1-34) analog; osteoanabolic agent
Teriparatide
Recombinant human parathyroid hormone fragment PTH(1-34); bone-forming (anabolic) osteoporosis agent
Mechanism: Abaloparatide
Abaloparatide is an injected bone-building drug that signals the skeleton to form new bone faster than it is broken down.
Teriparatide
In plain terms, teriparatide is a piece of the body's own parathyroid hormone that, when injected once a day, signals bone-building cells to add new bone.
United States (FDA): Abaloparatide
Approved. Postmenopausal women with osteoporosis at high risk of fracture (April 2017, brand Tymlos); expanded to men with osteoporosis at high risk of fracture (December 2022).
Teriparatide
Approved as Forteo (NDA 021318) on 26 November 2002, the first anabolic osteoporosis agent, for postmenopausal women and men at high fracture risk and, later, glucocorticoid-induced osteoporosis.
European Union (EMA): Abaloparatide
Authorised across the EU (Eladynos) for postmenopausal osteoporosis, December 2022, following an earlier 2018 refusal.
Teriparatide
Authorised as Forsteo on 10 June 2003 (Eli Lilly Nederland B.V.) for osteoporosis in postmenopausal women, men at increased fracture risk, and glucocorticoid-induced osteoporosis. Teriparatide biosimilars are also authorised.
Australia (TGA): Abaloparatide
Registered on the ARTG as a prescription medicine (Eladynos, sponsor Theramex Australia) for postmenopausal osteoporosis, November 2024.
Teriparatide
Registered on the ARTG (Forteo, ARTG 80333) as a prescription medicine; teriparatide biosimilars such as Terrosa are also registered.
WADA: Abaloparatide
Not listed on the WADA Prohibited List; parathyroid hormone analogs are not among the prohibited peptide-hormone classes.
Teriparatide
Not listed as a prohibited substance on the WADA Prohibited List (2026). Parathyroid hormone analogs are not classified as prohibited in or out of competition.
Evidence grade: Abaloparatide
A
Teriparatide
A
Tracked clinical trials: Abaloparatide
25
Teriparatide
182
Full profile: Abaloparatide
Abaloparatide profile
Teriparatide
Teriparatide profile

Comparison of Abaloparatide and Teriparatide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Abaloparatide	Teriparatide
Class	Synthetic parathyroid hormone-related protein (PTHrP 1-34) analog; osteoanabolic agent	Recombinant human parathyroid hormone fragment PTH(1-34); bone-forming (anabolic) osteoporosis agent
Mechanism	Abaloparatide is an injected bone-building drug that signals the skeleton to form new bone faster than it is broken down.	In plain terms, teriparatide is a piece of the body's own parathyroid hormone that, when injected once a day, signals bone-building cells to add new bone.
United States (FDA)	Approved. Postmenopausal women with osteoporosis at high risk of fracture (April 2017, brand Tymlos); expanded to men with osteoporosis at high risk of fracture (December 2022).	Approved as Forteo (NDA 021318) on 26 November 2002, the first anabolic osteoporosis agent, for postmenopausal women and men at high fracture risk and, later, glucocorticoid-induced osteoporosis.
European Union (EMA)	Authorised across the EU (Eladynos) for postmenopausal osteoporosis, December 2022, following an earlier 2018 refusal.	Authorised as Forsteo on 10 June 2003 (Eli Lilly Nederland B.V.) for osteoporosis in postmenopausal women, men at increased fracture risk, and glucocorticoid-induced osteoporosis. Teriparatide biosimilars are also authorised.
Australia (TGA)	Registered on the ARTG as a prescription medicine (Eladynos, sponsor Theramex Australia) for postmenopausal osteoporosis, November 2024.	Registered on the ARTG (Forteo, ARTG 80333) as a prescription medicine; teriparatide biosimilars such as Terrosa are also registered.
WADA	Not listed on the WADA Prohibited List; parathyroid hormone analogs are not among the prohibited peptide-hormone classes.	Not listed as a prohibited substance on the WADA Prohibited List (2026). Parathyroid hormone analogs are not classified as prohibited in or out of competition.
Evidence grade	A	A
Tracked clinical trials	25	182
Full profile	Abaloparatide profile	Teriparatide profile

Common questions

What is the difference between Abaloparatide and Teriparatide?: Abaloparatide is classified as: Synthetic parathyroid hormone-related protein (PTHrP 1-34) analog; osteoanabolic agent. Teriparatide is classified as: Recombinant human parathyroid hormone fragment PTH(1-34); bone-forming (anabolic) osteoporosis agent. Abaloparatide is approved for one or more medical uses in at least one major jurisdiction. Teriparatide is approved for one or more medical uses in at least one major jurisdiction.
Is Abaloparatide or Teriparatide approved?: Abaloparatide is approved for one or more medical uses in at least one major jurisdiction. Teriparatide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Abaloparatide and Teriparatide?: Peptide Science Daily tracks 25 registered clinical trials for Abaloparatide (evidence grade A) and 182 for Teriparatide (evidence grade A).